Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $65.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 71.63% year-over-year to $65.0 million, compared with a TTM value of $65.0 million through Sep 2025, down 71.63%, and an annual FY2024 reading of $203.1 million, down 11.56% over the prior year.
  • Total Non-Current Liabilities was $65.0 million for Q3 2025 at Atara Biotherapeutics, up from $31.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $259.2 million in Q1 2024 and bottomed at $31.2 million in Q2 2025.
  • Average Total Non-Current Liabilities over 4 years is $188.1 million, with a median of $224.0 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities surged 35.23% in 2023, then tumbled 86.09% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $244.2 million in 2022, then fell by 5.96% to $229.7 million in 2023, then decreased by 11.56% to $203.1 million in 2024, then crashed by 67.98% to $65.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ATRA at $65.0 million in Q3 2025, $31.2 million in Q2 2025, and $114.0 million in Q1 2025.